These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 27272171

  • 1. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
    Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA.
    Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171
    [Abstract] [Full Text] [Related]

  • 2. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.
    Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S, Keystone EC.
    Arthritis Rheumatol; 2016 Dec; 68(12):2867-2877. PubMed ID: 27389975
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
    Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S.
    Arthritis Rheumatol; 2016 Dec; 68(12):2857-2866. PubMed ID: 27390150
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials.
    Mohamed MF, Zeng J, Marroum PJ, Song IH, Othman AA.
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):208-216. PubMed ID: 29688617
    [Abstract] [Full Text] [Related]

  • 5. Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.
    Klünder B, Mohamed MF, Othman AA.
    Clin Pharmacokinet; 2018 Aug; 57(8):977-988. PubMed ID: 29076110
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.
    Khatri A, Goss S, Jiang P, Mansikka H, Othman AA.
    Clin Pharmacokinet; 2018 May; 57(5):613-623. PubMed ID: 28744796
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L, Gidal B, Blakey G, Tayo B, Morrison G.
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Cohen S, Beebe JS, Chindalore V, Guan S, Hassan-Zahraee M, Saxena M, Xi L, Hyde C, Koride S, Levin R, Lubaczewski S, Salganik M, Sloan A, Stevens E, Peeva E, Vincent MS, Martin DA, Chu M.
    Arthritis Res Ther; 2024 Jun 06; 26(1):117. PubMed ID: 38845046
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
    Sun L, Ding L, Wang Y, Zhou W, Yan Z, Sun W, Zhang H, Ou N, Chen X.
    Drugs R D; 2012 Mar 01; 12(1):17-28. PubMed ID: 22339483
    [Abstract] [Full Text] [Related]

  • 18. Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials.
    Khatri A, Othman AA.
    J Clin Pharmacol; 2018 Jun 01; 58(6):803-813. PubMed ID: 29364523
    [Abstract] [Full Text] [Related]

  • 19. Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
    Mohamed MF, Gopalakrishnan S, Teixeira HD, Othman AA.
    J Clin Pharmacol; 2021 May 01; 61(5):628-635. PubMed ID: 33156550
    [Abstract] [Full Text] [Related]

  • 20. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
    Vanhoutte F, Mazur M, Voloshyn O, Stanislavchuk M, Van der Aa A, Namour F, Galien R, Meuleners L, van 't Klooster G.
    Arthritis Rheumatol; 2017 Oct 01; 69(10):1949-1959. PubMed ID: 28622463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.